Insun Kang

Array ( [id] => 17702951 [patent_doc_number] => 20220202957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => LONG-LASTING ANALGESIA VIA TARGETED IN VIVO EPIGENETIC REPRESSION [patent_app_type] => utility [patent_app_number] => 17/602150 [patent_app_country] => US [patent_app_date] => 2020-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17602150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17563461 [patent_doc_number] => 20220127610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA [patent_app_type] => utility [patent_app_number] => 17/434727 [patent_app_country] => US [patent_app_date] => 2020-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17434727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17579126 [patent_doc_number] => 20220135981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => TARGETING SENESCENT CELLS [patent_app_type] => utility [patent_app_number] => 17/433284 [patent_app_country] => US [patent_app_date] => 2020-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25236 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -60 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17433284 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20142855 [patent_doc_number] => 12377170 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-08-05 [patent_title] => Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy [patent_app_type] => utility [patent_app_number] => 17/432417 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 16 [patent_no_of_words] => 20122 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17432417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505483 [patent_doc_number] => 20220098585 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 17/426511 [patent_app_country] => US [patent_app_date] => 2020-01-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 136745 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17426511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17577054 [patent_doc_number] => 20220133909 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => HIGHLY EFFICIENT TRANSDUCTION AND LATERAL SPREAD IN THE RETINA BY A NOVEL AAV VIRUS ENHANCED BY RATIONAL DESIGN [patent_app_type] => utility [patent_app_number] => 17/425292 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12615 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425292 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503424 [patent_doc_number] => 20220096526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF OCULAR DISEASES AND CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/425058 [patent_app_country] => US [patent_app_date] => 2020-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480548 [patent_doc_number] => 20220088052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => TFAP2 INHIBITION FOR TREATING CARDIAC DISEASE INVOLVING FIBRO-FATTY REPLACEMENT [patent_app_type] => utility [patent_app_number] => 17/424505 [patent_app_country] => US [patent_app_date] => 2020-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17424505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17506556 [patent_doc_number] => 20220099659 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => Human Genomic Construct Reporter Cells and Mouse Models to Screen Therapeutics against Microglia-expressed Disease Associated Genes [patent_app_type] => utility [patent_app_number] => 17/425580 [patent_app_country] => US [patent_app_date] => 2020-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29344 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17472467 [patent_doc_number] => 20220079971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => SERPINC1 iRNA Compositions and Methods of Use Thereof [patent_app_type] => utility [patent_app_number] => 17/422982 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29182 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17422982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480547 [patent_doc_number] => 20220088051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => DOUBLE-STRANDED OLIGONUCLEOTIDE TARGETING DKK1 GENE, CONSTRUCT INCLUDING SAME, AND HAIR LOSS PREVENTION OR HAIR GROWTH COMPOSITION CONTAINING SAME [patent_app_type] => utility [patent_app_number] => 17/423372 [patent_app_country] => US [patent_app_date] => 2020-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12363 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482587 [patent_doc_number] => 20220090091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => COMPOSITIONS OF POLYNUCLEIC ACID VECTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/421596 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 297 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17421596 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444130 [patent_doc_number] => 20220064635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => CRISPR COMPOSITIONS AND METHODS FOR PROMOTING GENE EDITING OF ADENOSINE DEAMINASE 2 (ADA2) [patent_app_type] => utility [patent_app_number] => 17/420934 [patent_app_country] => US [patent_app_date] => 2020-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17420934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17444137 [patent_doc_number] => 20220064642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => OLIGOMERIC NUCLEIC ACID MOLECULE AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/419569 [patent_app_country] => US [patent_app_date] => 2019-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12441 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503441 [patent_doc_number] => 20220096543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => TOLLIP DEFICIENT NEUTROPHILS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/418037 [patent_app_country] => US [patent_app_date] => 2019-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17418037 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460271 [patent_doc_number] => 20220073576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => CODON-OPTIMISED COMPLEMENT FACTOR I [patent_app_type] => utility [patent_app_number] => 17/415852 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18249 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17415852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399953 [patent_doc_number] => 20220042043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => RECOMBINANT VECTORS FOR THE LONG TERM TREATMENT OF MUCCHOPOLYSACHARIDOSIS [patent_app_type] => utility [patent_app_number] => 17/413973 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413973 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17981273 [patent_doc_number] => 20220347309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => PYRROLOBENZODIAZEPINE RESISTANCE [patent_app_type] => utility [patent_app_number] => 17/414622 [patent_app_country] => US [patent_app_date] => 2019-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17414622 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520752 [patent_doc_number] => 20220106601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => Antisense Drug Against the Human Intercellular Adhesion Molecule 1 (ICAM-1) [patent_app_type] => utility [patent_app_number] => 17/425081 [patent_app_country] => US [patent_app_date] => 2019-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4436 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425081 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17398027 [patent_doc_number] => 20220040117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => ANELLOSOMES FOR DELIVERING INTRACELLULAR THERAPEUTIC MODALITIES [patent_app_type] => utility [patent_app_number] => 17/413123 [patent_app_country] => US [patent_app_date] => 2019-12-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 143847 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413123 [rel_patent_id] =>[rel_patent_doc_number] =>)